Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...

Shares of Moderna MRNA rose 13% in the past week after the company announced preliminary sales for the full-year 2025, as ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

Nov 16 (Reuters) - Wall Street's main indexes rose on Monday after Moderna became the second U.S. company in a week to report positive results from its COVID-19 vaccine trial, raising hopes of a ...

CAPE TOWN (Reuters) - South Africa's Afrigen Biologics has used the publicly available sequence of Moderna Inc's mRNA COVID-19 vaccine to make its own version of the shot, which could be tested in ...